Neuroinflammation and depression: The role of indoleamine 2,3-dioxygenase (IDO) as a molecular pathway

Psychosomatic Medicine

Volumn 74, Issue 7, 2012, Pages 668-672

  Sublette, M Elizabeth ^a,b   Postolache, Teodor T ^c,d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Howard Hughes Medical Institute   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d VA Capitol Network MIRECC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CITALOPRAM; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; QUINOLINIC ACID; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; COMORBIDITY; DEPRESSION; FOOD INTAKE; HUMAN; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TRYPTOPHAN METABOLISM;

EID: 84866333507     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e318268de9f     Document Type: Note

References (64)

1. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008;31:464-8.
2. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008;13:501-10. (Pubitemid 351965454)
3. Scrandis DA, Langenberg P, Tonelli LH, Sheikh TM, Manogura AC, Alberico LA, Hermanstyne T, Fuchs D, Mighty H, Hasday JD, Boteva K, Postolache TT. Prepartum depressive symptoms correlate positively with C-reactive protein levels and negatively with tryptophan levels: a preliminary report. Int J Child Health Hum Dev 2008;1:167-74.
4. Frommberger UH, Bauer J, Haselbauer P, Fräulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997;247:228-33. (Pubitemid 27399827)
5. Kenis G, Maes M. Effects of antidepressants on the production of cyto-kines. Int J Neuropsychopharmacol 2002;5:401-12.
6. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301-9.
7. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neu-ropsychopharmacol Biol Psychiatry 2007;31:1044-53.
8. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-alphaYinduced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538-44. (Pubitemid 40897037)
9. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry 2009;22:32-6.
10. Werner ER, Bitterlich G, Fuchs D, Hausen A, Reibnegger G, Szabo G, Dierich MP, Wachter H. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987;41:273-80. (Pubitemid 17109654)
11. Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990;3:873-6. (Pubitemid 20330669)
12. Maes M, Meltzer HY, Scharpe S, Bosmans E, Suy E, De Meester I, Calabrese J, Cosyns P. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993;49:151-65.
13. Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, Dwork AJ, Arango V. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000;57:729-38. (Pubitemid 30650106)
14. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468-73. (Pubitemid 34712898)
15. Feder A, Skipper J, Blair JR, Buchholz K, Mathew SJ, Schwarz M, Doucette JT, Alonso A, Collins KA, Neumeister A, Charney DS. Tryp-tophan depletion and emotional processing in healthy volunteers at high risk for depression. Biol Psychiatry 2011;69:804-7.
16. Salomon RM, Kennedy JS, Johnson BW, Schmidt DE, Kwentus J, Gwirtsman HE, Ebert MH. Association of a critical CSF tryptophan threshold level with depressive relapse. Neuropsychopharmacology 2003;28:956-60.
17. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, Heninger GR, Charney DS. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999; 46:212-20. (Pubitemid 29320073)
18. Neumeister A, Nugent AC, Waldeck T, Geraci M, Schwarz M, Bonne O, Bain EE, Luckenbaugh DA, Herscovitch P, Charney DS, Drevets WC. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry 2004;61:765-73. (Pubitemid 39031116)
19. Neumeister A, Konstantinidis A, Stastny J, Schwarz MJ, Vitouch O, Willeit M, Praschak-Rieder N, Zach J, de Zwaan M, Bondy B, Ackenheil M, Kasper S. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry 2002;59:613-20. (Pubitemid 34747241)
20. Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O, Herscovitch P, Goldman D, Drevets WC, Charney DS. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry 2006;63:978-86. (Pubitemid 44330456)
21. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393-403.
22. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuro-protection. J Affect Disord 2007;98:143-51. (Pubitemid 46048912)
23. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983;219:316-8. (Pubitemid 13222319)
24. Dantzer R, O'Connor J, Freund G, Johnson R, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56. (Pubitemid 350295688)
25. Fu X, Zunich SM, O'Connor JC, Kavelaars A, Dantzer R, Kelley KW. Central administration of lipopolysaccharide induces depressive-like behavior invivo and activates brain indoleamine 2, 3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation 2010;7:43.
26. Moreau M, Lestage J, Verrier D, Mormede C, Kelley KW, Dantzer R, Castanon N. Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2, 3-dioxygenase in mice. J Infect Dis 2005;192:537-44. (Pubitemid 41023135)
27. O'Connor JC, Lawson MA, Andre C, Briley EM, Szegedi SS, Lestage J, Castanon N, Herkenham M, Dantzer R, Kelley KW. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009;182:3202-12.
28. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691-6. (Pubitemid 34712909)
29. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpe S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002;71:1837-48. (Pubitemid 34880232)
30. Kohl C, Walch T, Huber R, Kemmler G, Neurauter G, Fuchs D, Solder E, Schrocksnadel H, Sperner-Unterweger B. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord 2005;86:135-42. (Pubitemid 40780025)
31. Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, Mann JJ, Postolache TT. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011;25:1272-8.
32. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011;25:335-9.
33. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Björkqvist M, Träskman-Bendz L, Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009;66:287-92.
34. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008;42:151-7. (Pubitemid 350061255)
35. Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K, Schnabel A, Möller HJ, Chen HH, Postolache TT. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008;117:198-206. (Pubitemid 351207982)
36. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011;8:94.
37. Elovainio M, Hurme M, Jokela M, Pulkki-Ra°back L, Kivimäki M, Hintsanen M, Hintsa T, Lehtimäki T, Viikari J, Raitakari O, Keltikangas-Järvinen L. Indoleamine 2, 3-dioxygenase (IDO) activation and depressive symptoms: results from the Young Finns Study. Psychosom Med 2012;74:675-681.
38. Salmela-Aro K, Nurmi JE, Saisto T, Halmesmaki E. Goal reconstruction and depressive symptoms during the transition to motherhood: evidence from two cross-lagged longitudinal studies. J Pers Soc Psychol 2001;81:1144-59. (Pubitemid 33594535)
39. Pertovaara M, Raitala A, Juonala M, Lehtimaki T, Huhtala H, Oja SS, Jokinen E, Viikari JS, Raitakari OT, Hurme M. Indoleamine 2, 3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 2007;148:106-11. (Pubitemid 46364993)
40. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105. (Pubitemid 37432885)
41. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31. (Pubitemid 43083561)
42. Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord 2004;82:447-52.
43. Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, Lehtonen J, Vartiainen E. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 2001;52:529-31. (Pubitemid 32275317)
44. Colangelo LA, He K, Whooley MA, Daviglus ML, Liu K. Higher dietary intake of long-chain omega-3 polyunsaturated fatty acids is inversely associated with depressive symptoms in women. Nutrition 2009;25:1011-9.
45. Maes M, Smith RS. Fatty acids, cytokines, and major depression. Biol Psychiatry 1998;43:313-4.
46. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S-19S. (Pubitemid 44713092)
47. Timonen M, Jokelainen J, Herva A, Zitting P, Meyer-Rochow VB, Rasanen P. Presence of atopy in first-degree relatives as a predictor of a female proband's depression: results from the Northern Finland 1966 Birth Cohort. J Allergy Clin Immunol 2003;111:1249-54.
48. Timonen M, Jokelainen J, Silvennoinen-Kassinen S, Herva A, Zitting P, Xu B, Peltola O, Rasanen P. Association between skin test diagnosed atopy and professionally diagnosed depression: a Northern Finland 1966 Birth Cohort study. Biol Psychiatry 2002;52:349-55.
49. Timonen M, Jokelainen J, Hakko H, Silvennoinen-Kassinen S, Meyer-Rochow VB, Herva A, Rasanen P. Atopy and depression: results from the Northern Finland 1966 Birth Cohort Study. Mol Psychiatry 2003;8:738-44.
50. Hayaishi O. Biochemical and Medical Aspects of Tryptophan Metabolism. Amsterdam, the Netherlands: Elsevier/North Holland; 1980.
51. Ohira K, Hagihara H, Toyama K, Takao K, Kanai M, Funakoshi H, Nakamura T, Miyakawa T. Expression of tryptophan 2, 3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Brain 2010;3:26.
52. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. Alterations in kynur-enine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 2008;52:1297-303.
53. Salter M, Pogson CI. The role of tryptophan 2, 3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J 1985; 229:499-504. (Pubitemid 15232058)
54. Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, Laye S, Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011;70:175-82.
55. Neurauter G, Schrocksnadel K, Scholl-Burgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, Fuchs D. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008;9:622-7.
56. Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J Neuroimmunol 2001;120:190-8. (Pubitemid 33016739)
57. Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 2010; 36:211-8.
58. Muller N, Myint AM, Schwarz MJ. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des 2011;17:130-6.
59. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997;43:2424-6. (Pubitemid 28022985)
60. Herve C, Beyne P, Jamault H, Delacoux E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B Biomed Appl 1996;675:157-61. (Pubitemid 26036980)
61. Gal EM, Sherman AD. L-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 1980;5:223-39. (Pubitemid 10134133)
62. Smith AK, Simon JS, Gustafson EL, Noviello S, Cubells JF, Epstein MP, Devlin DJ, Qiu P, Albrecht JK, Brass CA, Sulkowski MS, McHutchinson JG, Miller AH. Association of a polymorphism in the indoleamine-2, 3-dioxygenase gene and interferon-alphaYinduced depression in patients with chronic hepatitis C. Mol Psychiatry 2011;17:781-9.
63. Cutler JA, Rush AJ, McMahon FJ, Laje G. Common genetic variation in the indoleamine-2, 3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J Psychopharmacol 2012;26:360-7.
64. Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ. Indoleamine 2, 3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 2011;18:2257-62.